Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413.
Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight (85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase III trial.
Sekine
I
I
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-city, Chiba, Japan.
Nishiwaki
Y
Y
Kakinuma
R
R
Kubota
K
K
Hojo
F
F
Matsumoto
T
T
Ohmatsu
H
H
Yokozaki
M
M
Goto
K
K
Miyamoto
T
T
Takafuji
J
J
Kodama
T
T
D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use; D008875:Middle Aged; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D002945:Cisplatin; D003907:Dexamethasone; D017829:Granisetron; D008787:Metoclopramide